[1] |
ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia.
Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
|
[2] |
CHEN Chenxin, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, HE Jia.
Combination of zero-inflated model and Dirichlet process in detection of adverse reaction signals during post-marketing surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 651-654.
|
[3] |
PAN Zhemin, XU Sheng, ZHENG Yi, CHEN Chenxin, LIU Yongmei, ZHANG Pengpeng, YE Xiaofei, HE Jia.
Comparison of likelihood ratio tests in post-marketing safety surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 655-660.
|
[4] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[5] |
WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan.
Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
|
[6] |
SUN Yixin, LIU Zhike, ZHAN Siyan.
Scoping review of near real-time surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67.
|
[7] |
FENG Jingnan, ZHAO Houyu, LIU Zhike, ZHAN Siyan.
Self-controlled tree temporal scan statistic in active surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 68-73.
|
[8] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|
[9] |
ZHONG Lumiao, DU Juan, DENG Hua, WANG Yafeng, QIU Ping, ZENG Linggui.
Thoughts on design and quality management of active safety surveillance research of traditional Chinese medicine injections initiated by Marketing Authorization Holder
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 994-998.
|
[10] |
SHEN Chuanyong, SONG Yana, ZHAO Yan, ZHENG Lijia, ZHAO Yifei, LI Dong.
Thoughts on constructing vigilance system of Chinese medical device in the new era
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 697-701.
|
[11] |
TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei.
Progress in the application of real-world data in post-market surveillance of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238.
|
[12] |
ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana.
Introduction and inspiration of international medical device regulators forum patient registry guidelines
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
|
[13] |
MENG Ruogu, ZHUO Lin, QIAO Rui, LIU Yuqiang, SUN Feng, ZHAN Siyan.
Application Values of Real-World Evidence in Post-Marketing Surveillances and Evaluation for Drug Safety
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 624-627.
|
[14] |
CHEN Feng.
Latest Development of International Pharmacovigilance and Its Implications
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 867-870.
|
[15] |
LI Xiaoyang, GUO Daihong, LIU Siyuan, YANG Hongyi, YAO Chong, QI Zhen.
Automatic Surveillance of Cases of Cefoperazone Sodium and Sulbactam Sodium-related Thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 890-893.
|